{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T12:16:09Z","timestamp":1742386569424},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2009,5,3]],"date-time":"2009-05-03T00:00:00Z","timestamp":1241308800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1007\/s00417-009-1093-7","type":"journal-article","created":{"date-parts":[[2009,5,4]],"date-time":"2009-05-04T20:42:25Z","timestamp":1241469745000},"page":"1057-1067","source":"Crossref","is-referenced-by-count":11,"title":["Dose-related changes in retinal function and PKC-alpha expression in rabbits on vigabatrin medication"],"prefix":"10.1007","volume":"247","author":[{"given":"Ulrika","family":"Kjellstr\u00f6m","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anitha","family":"Bruun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fredrik","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sten","family":"Andr\u00e9asson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vesna","family":"Ponjavic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,5,3]]},"reference":[{"key":"1093_CR1","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1046\/j.1528-1157.2003.04203.x","volume":"44","author":"GJ Sills","year":"2003","unstructured":"Sills GJ, Butler E, Forrest RN, Patsalos PN, Brodie MJ (2003) Vigabatrin, but not gabapentin or topiramat, produces concentration-related effects on enzymes and intermediates of the GABA shunt in rat brain and retina. Epilepsia 44:886\u2013892. doi: 10.1046\/j.1528-1157.2003.04203.x","journal-title":"Epilepsia"},{"key":"1093_CR2","first-page":"1694","volume":"314","author":"JT Backstr\u00f6m","year":"1997","unstructured":"Backstr\u00f6m JT, Hinke RL, Flicker MR (1997) Severe persistent visual field constriction associated with vigabatrin. BMJ 314:1694\u20131695","journal-title":"BMJ"},{"key":"1093_CR3","first-page":"1694","volume":"314","author":"N Blackwell","year":"1997","unstructured":"Blackwell N, Hayllar J, Kelly G (1997) Severe persistent visual field constriction associated with vigabatrin. BMJ 314:1694 letter","journal-title":"BMJ"},{"key":"1093_CR4","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/bmj.314.7075.180","volume":"314","author":"T Eke","year":"1997","unstructured":"Eke T, Talbot JF, Lawden MC (1997) Severe persistent visual field constriction associated with vigabatrin. BMJ 314:180\u2013181","journal-title":"BMJ"},{"key":"1093_CR5","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1136\/bmj.314.7087.1130","volume":"314","author":"GA Harding","year":"1997","unstructured":"Harding GA (1997) Severe persistent visual field constriction associated with vigabatrin. BMJ 314:1694 letter","journal-title":"BMJ"},{"key":"1093_CR6","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/bmj.314.7095.1693a","volume":"314","author":"EA Wilson","year":"1997","unstructured":"Wilson EA, Brodie MJ (1997) Severe persistent visual field constriction associated with vigabatrin. BMJ 314:1693 letter","journal-title":"BMJ"},{"key":"1093_CR7","first-page":"1694","volume":"314","author":"ICK Wong","year":"1997","unstructured":"Wong ICK, Mawer GE, Sander JWAS (1997) Severe persistent visual field constriction associated with vigabatrin. BMJ 314:1694\u20131695","journal-title":"BMJ"},{"key":"1093_CR8","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1016\/S0161-6420(99)90345-7","volume":"106","author":"H Daneshvar","year":"1999","unstructured":"Daneshvar H, Racette MA, Coupland SG, Kertes PJ, Guberman A, Zackon D (1999) Symptomatic and asymptomatic visual loss in patients taking vigabatrin. Ophthalmology 106:1792\u20131798. doi: 10.1016\/S0161-6420(99)90345-7","journal-title":"Ophthalmology"},{"key":"1093_CR9","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1212\/WNL.53.5.922","volume":"53","author":"R K\u00e4lvi\u00e4nen","year":"1999","unstructured":"K\u00e4lvi\u00e4nen R, Nousianen I, M\u00e4nyj\u00e4rvi M, Nikoskelainen E, Partanen J, Partanen K, Riekkinen P (1999) Vigabatrin, a GABAergic antiepileptic drug, cause concentric visual field defects. Neurology 53:922\u2013926","journal-title":"Neurology"},{"issue":"2","key":"1093_CR10","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1528-1167.2006.00422.x","volume":"47","author":"P Kinirons","year":"2006","unstructured":"Kinirons P, Cavalleri GL, Rourke DO, Doherty CP, Reid I, Logan P, Liggan B, Delanty N (2006) Vigabatrin retinopathy in an Irish cohort: lack of correlation with dose. Epilepsia 47(2):311\u2013317. doi: 10.1111\/j.1528-1167.2006.00422.x","journal-title":"Epilepsia"},{"key":"1093_CR11","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/jnnp.74.3.339","volume":"74","author":"GL Krauss","year":"2003","unstructured":"Krauss GL, Johnson MA, Sheth S, Miller NR (2003) A controlled study comparing visual function in patients treated with vigabatrin and tiagabine. J Neurol Neurosurg Psychiatry 74:339\u2013343. doi: 10.1136\/jnnp.74.3.339","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1093_CR12","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1136\/jnnp.67.6.716","volume":"67","author":"MC Lawden","year":"1999","unstructured":"Lawden MC, Eke T, Degg C, Harding GF, Wild JM (1999) Visual field defects associated with vigabatrin therapy. J Neurol Neurosurg Psychiatry 67:716\u2013722. doi: 10.1136\/jnnp.67.6.716","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1093_CR13","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1212\/WNL.53.9.2082","volume":"53","author":"NR Miller","year":"1999","unstructured":"Miller NR, Johnson MA, Paul SR, Girkin CA, Perry JD, Endres M, Krauss GL (1999) Visual dysfunction in patients receiving vigabatrin: clinical and electrophysiological findings. Neurology 53:2082\u20132087","journal-title":"Neurology"},{"key":"1093_CR14","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1136\/jnnp.73.3.327","volume":"73","author":"A Nicolson","year":"2002","unstructured":"Nicolson A, Leach JP, Chadwick DW, Smith DF (2002) The legacy of vigabatrin in a regional epilepsy clinic. J Neurol Neurosurg Psychiatry 73:327\u2013329. doi: 10.1136\/jnnp.73.3.327","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1093_CR15","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1212\/WNL.57.10.1916","volume":"57","author":"I Nousiainen","year":"2001","unstructured":"Nousiainen I, Mantyjarvi M, K\u00e4lviainen R (2001) No reversion in vigabatrin-associated visual field defects. Neurology 57:1916\u20131917","journal-title":"Neurology"},{"key":"1093_CR16","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1023\/A:1017589301855","volume":"102","author":"V Ponjavic","year":"2001","unstructured":"Ponjavic V, Andr\u00e9asson S (2001) Multifocal ERG and full-field ERG in patients on long-term vigabatrin medication. Doc Ophthalmol 102:63\u201372. doi: 10.1023\/A:1017589301855","journal-title":"Doc Ophthalmol"},{"key":"1093_CR17","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1111\/j.1528-1157.1999.tb01599.x","volume":"40","author":"JM Wild","year":"1999","unstructured":"Wild JM, Martinez C, Reinshagen G, Harding GF (1999) Characteristics of a unique visual field defect attributed to vigabatrin. Epilepsia 40:1784\u20131794. doi: 10.1111\/j.1528-1157.1999.tb01599.x","journal-title":"Epilepsia"},{"key":"1093_CR18","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1023\/A:1014603229383","volume":"104","author":"IF Comaish","year":"2002","unstructured":"Comaish IF, Gorman C, Brimlow GM (2002) The effects of vigabatrin on electrophysiology and visual fields in epileptics: a controlled study with a discussion of possible mechanisms. Doc Ophthalmol 104:195\u20132129. doi: 10.1023\/A:1014603229383","journal-title":"Doc Ophthalmol"},{"key":"1093_CR19","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S0161-6420(01)00638-8","volume":"108","author":"SG Coupland","year":"2001","unstructured":"Coupland SG, Zackon DH, Leonard BC, Ross TM (2001) Vigabatrin effect on inner retinal function. Ophthalmology 108:1493\u20131498. doi: 10.1016\/S0161-6420(01)00638-8","journal-title":"Ophthalmology"},{"key":"1093_CR20","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1023\/A:1014607331200","volume":"104","author":"HS Graniewski-Wijnands","year":"2002","unstructured":"Graniewski-Wijnands HS, van der Torren K (2002) Electro-ophthalmological recovery after withdrawal from vigabatrin. Doc Ophthalmol 104:189\u2013194. doi: 10.1023\/A:1014607331200","journal-title":"Doc Ophthalmol"},{"key":"1093_CR21","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1212\/WNL.55.3.347","volume":"55","author":"GA Harding","year":"2000","unstructured":"Harding GA, Wild JM, Robertson KA, Rietbrock S, Martinez C (2000) Separating the retinal electrophysiologic effects of vigabatrin$ treatment versus field loss. Neurology 55:347\u2013352. doi: 10.1159\/000006670","journal-title":"Neurology"},{"key":"1093_CR22","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1034\/j.1600-0420.2003.00085.x","volume":"81","author":"P Hardus","year":"2003","unstructured":"Hardus P, Verduin W, Berendschot T, Postma G, Stilma J, van Veelen C (2003) Vigabatrin: longterm follow-up of electrophysiology and visual field examinations. Acta Ophthalmol Scand 81:459\u2013465. doi: 10.1034\/j.1600-0420.2003.00085.x","journal-title":"Acta Ophthalmol Scand"},{"key":"1093_CR23","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1212\/WNL.55.1.40","volume":"55","author":"MA Johnson","year":"2000","unstructured":"Johnson MA, Krauss GL, Miller NR, Medura M, Paul SR (2000) Visual function loss from vigabatrin. effect of stopping the drug. Neurology 55:40\u201345","journal-title":"Neurology"},{"key":"1093_CR24","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1023\/A:1014615517996","volume":"104","author":"K Torren Van der","year":"2002","unstructured":"Van der Torren K, Graniewski-Wijnands HS, Polak BCP (2002) Visual field and electrophysiological abnormalities due to vigabatrin. Doc Ophthalmol 104:181\u2013188. doi: 10.1023\/A:1014615517996","journal-title":"Doc Ophthalmol"},{"key":"1093_CR25","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1023\/B:DOOP.0000005339.23258.8f","volume":"107","author":"CA Westall","year":"2003","unstructured":"Westall CA, Nobile R, Morong S, Buncic JR, Logan WJ, Panton CM (2003) Changes in the electroretinogram resulting from discontinuation of vigabatrin in children. Doc Ophthalmol 107:299\u2013309. doi: 10.1023\/B:DOOP.0000005339.23258.8f","journal-title":"Doc Ophthalmol"},{"key":"1093_CR26","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ics.2004.11.115","volume":"1278","author":"V Scaioli","year":"2005","unstructured":"Scaioli V, Franceschetti S, Binelli S et al (2005) Serial electrophysiological studies of the visual pathway in patients treated with vigabatrin. Int Congr Ser 1278:41\u201344. doi: 10.1016\/j.ics.2004.11.115","journal-title":"Int Congr Ser"},{"key":"1093_CR27","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1023\/A:1014644307518","volume":"104","author":"D Besch","year":"2002","unstructured":"Besch D, Kurtenbach A, Appfelstedt-Sylla E, Sadowski B, Dennig D, Asenbauer C, Zrenner E, Schiefer U (2002) Visual field constriction and electrophysiological changes associated with vigabatrin. Doc Ophthalmol 104:151\u2013170. doi: 10.1023\/A:1014644307518","journal-title":"Doc Ophthalmol"},{"key":"1093_CR28","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1212\/01.WNL.0000098938.80082.25","volume":"61","author":"J McDonagh","year":"2003","unstructured":"McDonagh J, Stephen LJ, Dolan FM, Parks S, Dutton GN, Kelly K, Keating D, Sills GJ, Brodie MJ (2003) Peripheral retinal dysfunction in patients taking vigabatrin. Neurology 61:1690\u20131694","journal-title":"Neurology"},{"issue":"1","key":"1093_CR29","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1528-1167.2007.01249.x","volume":"49","author":"M Conway","year":"2008","unstructured":"Conway M, Cubbidge RP, Hosking SL (2008) Visual field severity indices demonstrate dose-dependent visual loss from vigabatrin therapy. Epilepsia 49(1):108\u2013116","journal-title":"Epilepsia"},{"key":"1093_CR30","first-page":"262","volume":"42","author":"P Hardus","year":"2001","unstructured":"Hardus P, Verduin WM, Engelsman M (2001) Visual field loss associated with vigabatrin: quantification and relation to dosage. Epilepsia 42:262\u2013267. doi: 10.1046\/j.1528-1157.2001.15000.x","journal-title":"Epilepsia"},{"issue":"3","key":"1093_CR31","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2165\/00023210-200115030-00005","volume":"15","author":"R K\u00e4lvi\u00e4inen","year":"2001","unstructured":"K\u00e4lvi\u00e4inen R, Nousianen I (2001) Visual field defects with vigabatrin, epidemiology and therapeutic implications. CNS Drugs 15(3):217\u2013230. doi: 10.2165\/00023210-200115030-00005","journal-title":"CNS Drugs"},{"key":"1093_CR32","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1046\/j.1528-1157.2001.28600.x","volume":"42","author":"K Malmgren","year":"2001","unstructured":"Malmgren K, Ben-Menachem E, Fris\u00e9n L (2001) Vigabatrin visual toxicity: evaluation and dose dependence. Epilepsia 42:609\u2013615. doi: 10.1046\/j.1528-1157.2001.28600.x","journal-title":"Epilepsia"},{"key":"1093_CR33","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/bjo.84.5.499","volume":"84","author":"K Manuchehri","year":"2000","unstructured":"Manuchehri K, Goodman S, Siviter L, Nightingale S (2000) A controlled study of vigabatrin and visual abnormalities. Br J Ophthalmol 84:499\u2013505. doi: 10.1136\/bjo.84.5.499","journal-title":"Br J Ophthalmol"},{"key":"1093_CR34","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S1059-1311(00)90527-2","volume":"10","author":"S Toggweiler","year":"2001","unstructured":"Toggweiler S, Wieser HG (2001) Concentric visual field restriction under vigabatrin therapy:extent depends on the duration of drug intake. Seizure 10:420\u2013423","journal-title":"Seizure"},{"key":"1093_CR35","first-page":"244","volume":"15","author":"YL Tseng","year":"2006","unstructured":"Tseng YL, Lan MY, Lai SL, Huang FC, Tsai JJ (2006) Vigabatrin attributable visual field defects in patients with intractable partial epilepsy. Acta Neurol Taiwan 15:244\u2013250","journal-title":"Acta Neurol Taiwan"},{"key":"1093_CR36","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/sj.eye.6700168","volume":"16","author":"WD Newman","year":"2002","unstructured":"Newman WD, Tocher K, Acheson JF (2002) Vigabatrin associated visual field loss: a clinical audit to study prevalence, drug history and effects of drug withdrawal. Eye 16:567\u2013571. doi: 10.1038\/sj.eye.6700168","journal-title":"Eye"},{"key":"1093_CR37","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1023\/B:DOOP.0000036780.96560.74","volume":"108","author":"V Ponjavic","year":"2004","unstructured":"Ponjavic V, Gr\u00e4nse L, Kjellstr\u00f6m S, Andre\u00e1sson S, Bruun A (2004) Alterations in electroretinograms and retinal morphology in rabbits treated with vigabatrin. Doc Ophthalmol 108:125\u2013133. doi: 10.1023\/B:DOOP.0000036780.96560.74","journal-title":"Doc Ophthalmol"},{"key":"1093_CR38","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10633-006-0004-z","volume":"112","author":"U Kjellstr\u00f6m","year":"2006","unstructured":"Kjellstr\u00f6m U, Kjellstr\u00f6m S, Bruun A, Andr\u00e9asson S, Ponjavic V (2006) Retinal function in rabbits does not improve 4\u20135\u00a0months after terminating treatment with vigabatrin. Doc Ophthalmol 112:35\u201341. doi: 10.1007\/s10633-006-0004-z","journal-title":"Doc Ophthalmol"},{"key":"1093_CR39","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/ana.20081","volume":"55","author":"A Duboc","year":"2004","unstructured":"Duboc A, Hanoteau N, Simonutti M, Rudolf G, Nehlig A, Sahel JA, Picaud S (2004) Vigabatrin, the GABA-transaminas inhibitor, damages cone photoreceptors in rats. Ann Neurol 55:695\u2013705. doi: 10.1002\/ana.20081","journal-title":"Ann Neurol"},{"issue":"9","key":"1093_CR40","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1111\/j.0013-9580.2004.01004.x","volume":"45","author":"Y Izumi","year":"2004","unstructured":"Izumi Y, Ishikawa M, Benz AM, Izumi M, Zorumski CF, Thio LL (2004) Acute vigabatrin retinotoxicity in albino rats depends on light but not GABA. Epilepsia 45(9):1043\u20131048. doi: 10.1111\/j.0013-9580.2004.01004.x","journal-title":"Epilepsia"},{"key":"1093_CR41","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10633-004-3924-5","volume":"109","author":"K Gj\u00f6rloff","year":"2004","unstructured":"Gj\u00f6rloff K, Andr\u00e9asson S, Ehinger B (2004) Standardized full-field electroretinography in rabbits. Doc Ophthalmol 109:163\u2013168. doi: 10.1007\/s10633-004-3924-5","journal-title":"Doc Ophthalmol"},{"key":"1093_CR42","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1023\/B:DOOP.0000036793.44912.45","volume":"108","author":"MF Marmor","year":"2004","unstructured":"Marmor MF, Holder GE, Seelinger MW, Yamamoto S (2004) International society for clinical electrophysiology of vision. Standard for clinical electroretinography (2004 update). Doc Ophthalmol 108:107\u2013114. doi: 10.1023\/B:DOOP.0000036793.44912.45","journal-title":"Doc Ophthalmol"},{"key":"1093_CR43","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0197-0186(96)00049-6","volume":"30","author":"JM Wood","year":"1997","unstructured":"Wood JM, McCord RJ, Osborne NN (1997) Retinal protein kinase C. Neurochem Int 30:119\u2013136. doi: 10.1016\/S0197-0186(96)00049-6","journal-title":"Neurochem Int"},{"key":"1093_CR44","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1046\/j.1440-1681.1999.03152.x","volume":"26","author":"U Gr\u00fcnert","year":"1999","unstructured":"Gr\u00fcnert U (1999) Distribution of GABA A and glycine receptors in the mammalian retina. Clin Exp Pharm Phys 26:941\u2013944. doi: 10.1046\/j.1440-1681.1999.03152.x","journal-title":"Clin Exp Pharm Phys"},{"key":"1093_CR45","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/S0042-6989(97)00300-3","volume":"38","author":"H W\u00e4ssle","year":"1998","unstructured":"W\u00e4ssle H, Koulen P, Brandst\u00e4tter JH, Fletcher EL, Becker CM (1998) Glycine and GABA receptors in the mammalian retina. Vision Res 38:1411\u20131430. doi: 10.1016\/S0042-6989(97)00300-3","journal-title":"Vision Res"},{"key":"1093_CR46","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0074-7696(03)30005-1","volume":"230","author":"GP Lewis","year":"2003","unstructured":"Lewis GP, Fisher SK (2003) Up-regulation of glial fibrillary acidic protein in response to retinal injury: Its potential role in glial remodelling and a comparison to vimentin expression. Int Rev Cytol 230:263\u2013290. doi: 10.1016\/S0074-7696(03)30005-1","journal-title":"Int Rev Cytol"},{"key":"1093_CR47","first-page":"546","volume":"25","author":"JC Blanks","year":"1984","unstructured":"Blanks JC, Johnson LV (1984) Specific binding of peanut agglutinin to a class of retinal photoreceptor cells. Invest Ophthalmol Vis Sci 25:546\u2013557","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1093_CR48","first-page":"1951","volume":"32","author":"GS Hageman","year":"1991","unstructured":"Hageman GS, Johnson LV (1991) Structural and compositional analyses of isolated cone matrix sheaths. Invest Ophthalmol Vis Sci 32:1951\u20131957","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1093_CR49","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s10633-007-9108-3","volume":"117","author":"U Kjellstr\u00f6m","year":"2008","unstructured":"Kjellstr\u00f6m U, L\u00f6vestam-Adrian M, Andr\u00e9asson S, Ponjavic V (2008) Full-field ERG and visual fields in patients 5 years after discontinuing vigabatrin therapy. Doc Ophthalmol 117:93\u2013101. doi: 10.1007\/s10633-007-9108-3","journal-title":"Doc Ophthalmol"},{"key":"1093_CR50","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1017\/S0952523899164125","volume":"16","author":"DG Green","year":"1999","unstructured":"Green DG, Kapousta-Brenaeau NV (1999) A dissection of the ERG from the isolated rat retina with microelectrodes and drugs. Vis Neurosci 16:727\u2013741. doi: 10.1017\/S0952523899164125","journal-title":"Vis Neurosci"},{"key":"1093_CR51","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1152\/jn.1970.33.3.323","volume":"33","author":"RF Miller","year":"1970","unstructured":"Miller RF, Dowling JE (1970) Intracellular responses of M\u00fcller (glial) cells of mudpuppy retina: their relation to b-wave of the electroretinogram. J Neurophysiol 33:323\u2013341","journal-title":"J Neurophysiol"},{"key":"1093_CR52","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0028-3908(94)00141-E","volume":"34","author":"B Bettler","year":"1995","unstructured":"Bettler B, Mulle C (1995) Rewiev: neurotransmitter receptors II. AMPA and kainate receptors. Neuropharmacology 34:123\u2013139. doi: 10.1016\/0028-3908(94)00141-E","journal-title":"Neuropharmacology"},{"key":"1093_CR53","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0304-3940(00)00864-8","volume":"282","author":"CS Jung","year":"2000","unstructured":"Jung CS, Paik SJ, Bai SH (2000) Run up of gamma amino butyric acid (C) responses in catfish retinal cone-horizontal cell axon-terminals is modulated by protein kinase A and C. Neurosci Lett 282:53\u201356. doi: 10.1016\/S0304-3940(00)00864-8","journal-title":"Neurosci Lett"},{"issue":"10","key":"1093_CR54","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/0028-3908(95)00097-P","volume":"34","author":"NN Osborne","year":"1995","unstructured":"Osborne NN, Wood J, Muller A (1995) The influence of experimental ischemia on protein kinase C and the GABAergic system in the rabbit retina. Neuropharmacology 34(10):1279\u20131288. doi: 10.1016\/0028-3908(95)00097-P","journal-title":"Neuropharmacology"},{"issue":"12","key":"1093_CR55","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1007\/s00417-007-0646-x","volume":"245","author":"K Gj\u00f6rloff-Wallent\u00e9n","year":"2007","unstructured":"Gj\u00f6rloff-Wallent\u00e9n K, Malmsj\u00f6 M, Andr\u00e9asson S, Wackenfors A, Johansson K, Ghosh F (2007) Retinal function and PKC alpha expression after focal laser coagulation. Graefes Arch Clin Exp Ophthalmol 245(12):1815\u20131824. doi: 10.1007\/s00417-007-0646-x","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1093_CR56","first-page":"817","volume":"116","author":"K Ruether","year":"1998","unstructured":"Ruether K, Pung T, Kellner U, Schmitz B, Hartmann C, Seeliger M (1998) Electrophysiological evaluation of a patient with peripheral visual field contraction associated with vigabatrin. Arch Ophthalmol 116:817\u2013819","journal-title":"Arch Ophthalmol"},{"key":"1093_CR57","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1111\/j.1460-9568.2008.06175.x","volume":"27","author":"QP Wang","year":"2008","unstructured":"Wang QP, Jammoul F, Duboc A, Gong J, Simonutti M, Dubud E, Craft CM, Ye W, Sahel JA, Picaud S (2008) Treatment of epilepsy: the GABA-transaminase inhibitor, vigabatrin, induces neuronal plasticity in the mouse retina. Eur J Neurosci 27:2177\u20132187. doi: 10.1111\/j.1460-9568.2008.06175.x","journal-title":"Eur J Neurosci"},{"key":"1093_CR58","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/0042-6989(68)90041-2","volume":"8","author":"KT Brown","year":"1968","unstructured":"Brown KT (1968) The electrogram: its components and their origin. Vision Res 8:633\u2013677. doi: 10.1016\/0042-6989(68)90041-2","journal-title":"Vision Res"},{"key":"1093_CR59","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1017\/S0952523898154135","volume":"15","author":"MA Johnson","year":"1998","unstructured":"Johnson MA, Vardi N (1998) Regional differences in GABA and GAD immunoreactivity in rabbit horizontal cells. Vis Neurosci 15:743\u2013753","journal-title":"Vis Neurosci"},{"key":"1093_CR60","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0079-6123(08)63608-0","volume":"90","author":"MM Slaughter","year":"1992","unstructured":"Slaughter MM, Pan ZH (1992) The physiology of GABA B receptors in the vertebrate retina. Prog Brain Res 90:47\u201360. doi: 10.1016\/S0079-6123(08)63608-0","journal-title":"Prog Brain Res"},{"key":"1093_CR61","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1017\/S0952523800006799","volume":"12","author":"EV Famiglietti","year":"1995","unstructured":"Famiglietti EV, Sharpe SJ (1995) Regional topography of rod and immunocytochemically characterized \u201cblue\u201d and \u201cgreen\u201d cone photoreceptors in rabbit retina. Vis Neurosci 12:1151\u20131175","journal-title":"Vis Neurosci"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-009-1093-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00417-009-1093-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-009-1093-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T19:40:47Z","timestamp":1559072447000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00417-009-1093-7"}},"subtitle":["Effect of vigabatrin in the rabbit eye"],"short-title":[],"issued":{"date-parts":[[2009,5,3]]},"references-count":61,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["1093"],"URL":"https:\/\/doi.org\/10.1007\/s00417-009-1093-7","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5,3]]}}}